---
number: 2 Years
textFollowingNumber: instead of 17 years to get new treatments to patients
title: 17 years to 2 Year From Research to Treatment
description: >-
  By streamlining the clinical trial process through automation and
  decentralization, we can reduce the time from initial research to patient
  availability from 17 years to just 2 years
emoji: âš¡
featuredImage: treatment-time.jpg
source: 'https://dfda.earth'
published: true
editor: markdown
date: '2025-02-09T16:20:32.141Z'
dateCreated: '2025-02-09T16:20:32.141Z'
---

From initial research to clinical practice, new medical treatments take an average of [17 years](https://pmc.ncbi.nlm.nih.gov/articles/PMC3241518/) to complete the development process and reach patients.

Phase 1 clinical trials are used to determine the safety and effects of a new drug. These take 1-2 years.

At this point, it should be possible for patients to join a trials for the treatments with the most promise.

Through automation of administrative tasks, AI-assisted protocol development, and decentralized trial management, we can dramatically compress this timeline.

This acceleration means potentially life-saving treatments reach patients faster while maintaining rigorous safety standards through automated monitoring and real-time data analysis.
